Search

Your search keyword '"Ozaka, M."' showing total 210 results
Start Over Author "Ozaka, M."
210 results on '"Ozaka, M."'

2. Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced/recurrent biliary tract cancer: the FUGA-BT (JCOG1113) randomized phase III clinical trial

Author

Morizane, C., Okusaka, T., Mizusawa, J., Katayama, H., Ueno, M., Ikeda, M., Ozaka, M., Okano, N., Sugimori, K., Fukutomi, A., Hara, H., Mizuno, N., Yanagimoto, H., Wada, K., Tobimatsu, K., Yane, K., Nakamori, S., Yamaguchi, H., Asagi, A., Yukisawa, S., Kojima, Y., Kawabe, K., Kawamoto, Y., Sugimoto, R., Iwai, T., Nakamura, K., Miyakawa, H., Yamashita, T., Hosokawa, A., Ioka, T., Kato, N., Shioji, K., Shimizu, K., Nakagohri, T., Kamata, K., Ishii, H., and Furuse, J.

Published
2019
Full Text
View/download PDF

3. Phase II study of reintroduction of oxaliplatin for advanced colorectal cancer in patients previously treated with oxaliplatin and irinotecan: RE-OPEN study

Author

Suenaga M, Mizunuma N, Matsusaka S, Shinozaki E, Ozaka M, Ogura M, and Yamaguchi T

Subjects
Therapeutics. Pharmacology, RM1-950
Abstract

Mitsukuni Suenaga,1 Nobuyuki Mizunuma,1 Satoshi Matsusaka,1 Eiji Shinozaki,1 Masato Ozaka,1 Mariko Ogura,1 Toshiharu Yamaguchi21Department of Gastroenterology, 2Department of Gastroenterological Surgery, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, JapanBackground: The effectiveness of reintroducing oxaliplatin in patients with metastatic colorectal cancer refractory to standard chemotherapy has not been verified. We performed a single-arm, open-label, Phase II study to evaluate the safety and efficacy of reintroducing oxaliplatin. Methods: Eligible patients had received prior chemotherapy including oxaliplatin and irinotecan that achieved a response or stable disease followed by confirmed disease progression ≥6 months previously during prior oxaliplatin-based therapy. The primary endpoint was the disease control rate (DCR) after 12 weeks of treatment starting. The DCR was defined as the sum of patients with complete response, partial response, and stable disease. Results: Thirty-three patients were enrolled. The median age was 62 (range: 35–77) years and the male/female ratio was 19/14. Eastern Cooperative Oncology Group performance status was 0 in 84.8%. Fourteen primary tumors were in the colon and 19 were in the rectum. All patients received modified FOLFOX6 as the protocol treatment. After 12 weeks of treatment starting, the DCR was 39.4% (95% confidence interval 21.8–57.0) and the response rate (complete response and partial response) was 6.1%. The median number of chemotherapy cycles was five and the median total dose of oxaliplatin was 425 mg/m2. Median progression-free survival time was 98 days and median overall survival was 300 days. The incidence of grade ≥1 and grade ≥3 allergic reactions was 28.1% and 3.1%, respectively. The incidence of grade ≥1 and grade ≥3 peripheral sensory neuropathy was 53.1% and 0%, respectively. There were no other severe adverse events and no treatment-related deaths.Conclusion: Reintroducing oxaliplatin can be both safe and effective. This may be a salvage option for patients with metastatic colorectal cancer who achieved a response or stable disease with prior oxaliplatin-based therapy followed by disease progression ≥6 months previously during prior oxaliplatin-based therapy.Keywords: reintroduction, oxaliplatin, FOLFOX, advanced colorectal cancer, salvage-line

Published
2015

4. A phase I/II study of biweekly capecitabine and irinotecan plus bevacizumab as second-line chemotherapy in patients with metastatic colorectal cancer

Author

Suenaga M, Mizunuma N, Matsusaka S, Shinozaki E, Ozaka M, Ogura M, Chin K, and Yamaguchi T

Subjects
Therapeutics. Pharmacology, RM1-950
Abstract

Mitsukuni Suenaga,1 Nobuyuki Mizunuma,1 Satoshi Matsusaka,1 Eiji Shinozaki,1 Masato Ozaka,1 Mariko Ogura,1 Keisho Chin,1 Toshiharu Yamaguchi2 1Department of Gastroenterology, 2Department of Gastroenterological Surgery, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Ariake, Koto-ku, Tokyo, Japan Background: Triweekly capecitabine plus irinotecan (XELIRI) is not completely regarded as a valid substitute for fluorouracil, leucovorin, and irinotecan (FOLFIRI) in metastatic colorectal cancer (mCRC) because of the potential for greater toxicity. We conducted a phase I/II study to assess the efficacy and safety of biweekly XELIRI plus bevacizumab (BV) as second-line chemotherapy for mCRC.Methods: Patients with mCRC who had received prior chemotherapy including oxaliplatin and BV and had a UGT1A1 genotype of wild-type or heterozygous for UGT1A1*6 or *28 were eligible for this study. Treatment comprised capecitabine 1,000 mg/m2 twice daily from the evening of day 1 to the morning of day 8, intravenous irinotecan on day 1, and BV 5 mg/kg on day 1 every 2 weeks. The phase I study consisted of two steps (irinotecan 150 and 180 mg/m2), and dose-limiting toxicity was assessed during the first treatment cycle. The primary endpoint of the phase II study was progression-free survival (PFS). Results: The recommended dose of irinotecan was determined to be 180 mg/m2 in the phase I study. Between November 2010 and August 2013, 44 patients were enrolled in phase II. The patients’ characteristics were as follows (N=44): median age, 60 years (range 32–80); male/female, 21/23; and UGT1A1 wild-type/heterozygous, 29/15. The median PFS was 6.8 months (95% confidence interval, 5.3–8.2 months), and the primary endpoint was met. Median overall survival was 18.3 months. The response rate was 22.7%. There was no significant difference in PFS or overall survival according to UGT1A1 status. Grade 3 or higher adverse events were mainly neutropenia in six patients and diarrhea in five patients. There were no other severe adverse events or treatment-related deaths.Conclusion: In mCRC patients with wild-type or heterozygous UGT1A1*6 or *28 genotype, biweekly XELIRI + BV is effective and feasible as second-line chemotherapy. Biweekly XELIRI + BV is considered a valid substitute for FOLFIRI + BV in mCRC. Keywords: XELIRI, bevacizumab, metastatic colorectal cancer, UGT1A1

Published
2015

7. 1521P Efficacy and safety of liposomal irinotecan plus S-1 in patients with metastatic pancreatic cancer after failure of first-line gemcitabine-based chemotherapy: Result of a phase I/II study

Author

Imaoka, H., Ikeda, M., Ozaka, M., Oshima, K., Okano, N., Shimizu, S., Tsumura, H., Komatsu, Y., Yamashita, T., Kataoka, S., Nagano, H., Hisano, T., Sasaki, M., Kobayashi, S., Fukushima, T., Mitsunaga, S., Furukawa, T., Hamauchi, S., Hedouin-Biville, F., and Ueno, M.

Published
2024
Full Text
View/download PDF

8. 1616O Nab-paclitaxel plus gemcitabine versus modified FOLFIRINOX or S-IROX in metastatic or recurrent pancreatic cancer (JCOG1611, GENERATE): A multicentred, randomized, open-label, three-arm, phase II/III trial

Author

Ohba, A., Ozaka, M., Ogawa, G., Okusaka, T., Kobayashi, S., Yamashita, T., Ikeda, M., Yasuda, I., Sugimori, K., Sasahira, N., Ikezawa, K., Miki, I., Okano, N., Mizuno, N., Furukawa, M., Shirakawa, H., Sano, Y., Katayama, H., Furuse, J., and Ueno, M.

Published
2023
Full Text
View/download PDF

9. 100P Hepatitis B virus (HBV)-related outcomes in patients (pts) with baseline HBV infection in the KEYNOTE-966 study of pembrolizumab (pembro) plus gemcitabine and cisplatin (gem/cis) for advanced biliary tract cancer (BTC)

Author

Chan, S.L., Finn, R.S., Valle, J.W., Kelley, R.K., Yoo, C., Furuse, J., Ren, Z., Yau, T., Klumpen, H.J., Ozaka, M., Verslype, C., Bouattour, M., Park, J.O., Edeline, J., Ueno, M., Vogel, A., Yu, L., Malhotra, U., Siegel, A.B., and Qin, S.

Published
2023
Full Text
View/download PDF

11. Liposomal irinotecan (nal-IRI) plus 5-fluorouracil/levoleucovorin (5 FU/LV) vs 5-FU/LV in Japanese patients (pts) with gemcitabine-refractory metastatic pancreatic cancer (mPAC)

Author

Ioka, T., primary, Nakamori, S., additional, Sugimori, K., additional, Kanai, M., additional, Ikeda, M., additional, Ozaka, M., additional, Furukawa, M., additional, Okusaka, T., additional, Kawabe, K., additional, Furuse, J., additional, Komatsu, Y., additional, Sato, A., additional, Shimizu, S., additional, Chugh, P., additional, Tang, R., additional, and Ueno, M., additional

Published
2019
Full Text
View/download PDF

12. Multicenter phase II trial of axitinib monotherapy for advanced biliary tract cancer refractory to gemcitabine-based chemotherapy

Author

Okano, N., primary, Ueno, M., additional, Morizane, C., additional, Yamanaka, T., additional, Ojima, H., additional, Ozaka, M., additional, Sasaki, M., additional, Takahara, N., additional, Kobayashi, S., additional, Morimoto, M., additional, Hosoi, H., additional, Nakai, Y., additional, Ikeda, M., additional, Maeno, S., additional, Nagashima, F., additional, Okusaka, T., additional, and Furuse, J., additional

Published
2019
Full Text
View/download PDF

14. Anticoagulant therapy for venous thromboembolism detected by Doppler ultrasound in patients with metastatic colorectal cancer receiving bevacizumab

Author

Suenaga M, Mizunuma N, Shinozaki E, Matsusaka S, Ozaka M, Ogura M, Chin K, and Yamaguchi T

Subjects
lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, lcsh:RC254-282
Abstract

Mitsukuni Suenaga, Nobuyuki Mizunuma, Eiji Shinozaki, Satoshi Matsusaka, Masato Ozaka, Mariko Ogura, Keisho Chin, Toshiharu Yamaguchi Department of Gastroenterology, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan Background: Doppler ultrasound imaging is useful for management of venous thromboembolism associated with a subclavicular implantable central venous access system in patients receiving bevacizumab (Bev). We investigated the efficacy and safety of our anticoagulant regimen based on Doppler findings.Methods: Patients aged ≤75 years with metastatic colorectal cancer, no history of thromboembolism, and no prior use of Bev received chemotherapy plus Bev. Doppler ultrasound imaging of the deep venous system to detect thrombosis was performed after the first course of Bev and repeated after the third course in patients with asymptomatic thrombosis. Indications for anticoagulant therapy in patients with asymptomatic thrombosis were as follows: enlarging thrombus (E), thrombus >40 mm in diameter (S), thrombus involving the superior vena cava (C), and decreased blood flow (V).Results: Among 79 patients enrolled in this study, asymptomatic thrombosis was detected in 56 patients (70.9%) by Doppler ultrasound imaging after the first course of Bev and there was no thrombus in 23 patients (29.1%). Of these 56 patients, 11 (19.6%) received anticoagulant therapy with warfarin, including eight after the first course and three after follow-up imaging. S + V was observed in four of 11 patients (36.4%), as well as V in two (18.2%), S + V + C in one (9.1%), E + S + V in one (9.1%), E + C in one (9.1%), E in one (9.1%), and C in one (9.1%). All patients resumed chemotherapy, including seven who resumed Bev. Improvement or stabilization of thrombi was achieved in ten patients (90.9%). Only one patient had symptomatic thromboembolism. Mild bleeding due to anticoagulant therapy occurred in six patients (54.5%), but there were no treatment-related severe adverse events or deaths. Severe thromboembolism was not observed in the other 68 patients.Conclusion: Our anticoagulant protocol for asymptomatic thrombosis detected by Doppler ultrasound imaging was effective at preventing severe thromboembolism during continued treatment with Bev. Keywords: venous thromboembolism, Bev, anticoagulant therapy, colorectal cancer

Published
2015

15. Risk factors for febrile neutropenia (FN) in unresectable/recurrent pancreatic cancer(PC) patients(pts) receiving FOLFIRINOX (FFX) from JASPAC06 study

Author

Sasaki, M., primary, Ueno, H., additional, Omae, K., additional, Goto, T., additional, Murohisa, G., additional, Mizuno, N., additional, Ozaka, M., additional, Kobayashi, S., additional, Uesugi, K., additional, Kobayashi, N., additional, Hayashi, H., additional, Sudo, K., additional, Okano, N., additional, Horita, Y., additional, Kamei, K., additional, Hosokawa, T., additional, Henmi, T., additional, Kobayashi, M., additional, Todaka, A., additional, and Fukutomi, A., additional

Published
2017
Full Text
View/download PDF

16. The impact of UGT1A1 genetic polymorphism on safety in unresectable pancreatic cancer patients receiving FOLFIRINOX therapy: A subset analysis of JASPAC 06 study

Author

Shirasu, H., primary, Omae, K., additional, Fujii, H., additional, Mizuno, N., additional, Ozaka, M., additional, Ueno, H., additional, Kobayashi, S., additional, Uesugi, K., additional, Kobayashi, N., additional, Hayashi, H., additional, Sudo, K., additional, Okano, N., additional, Horita, Y., additional, Kamei, K., additional, Seigo, Y., additional, Takafumi, H., additional, Henmi, T., additional, Kobayashi, M., additional, Todaka, A., additional, and Fukutomi, A., additional

Published
2017
Full Text
View/download PDF

17. Randomized phase II study of modified FOLFIRINOX versus gemcitabine plus nab-paclitaxel combination therapy for locally advanced pancreatic cancer: Japan Clinical Oncology Group Study (JCOG1407)

Author

Fukutomi, A., primary, Mizusawa, J., additional, Katayama, H., additional, Okusaka, T., additional, Ito, T., additional, Okano, N., additional, Mizuno, N., additional, Ikeda, M., additional, Ueno, M., additional, Shioji, K., additional, Ozaka, M., additional, Shimizu, S., additional, Sakamoto, Y., additional, Kondo, S., additional, Kawabe, K., additional, Eba, J., additional, Ishii, H., additional, Fukuda, H., additional, and Furuse, J., additional

Published
2017
Full Text
View/download PDF

18. FOLFIRINOX as second-line chemotherapy for advanced pancreatic cancer: A subset analysis from the nation-wide multicenter observational study (JASPAC06)

Author

Kobayashi, N., primary, Omae, K., additional, Horita, Y., additional, Ueno, H., additional, Mizuno, N., additional, Uesugi, K., additional, Sudo, K., additional, Ozaka, M., additional, Hayashi, H., additional, Okano, N., additional, Kamei, K., additional, Yamaguchi, A., additional, Kobayashi, S., additional, Suzuki, S., additional, Ishihara, S., additional, Uchiyama, T., additional, Todaka, A., additional, and Fukutomi, A., additional

Published
2017
Full Text
View/download PDF

23. Randomized phase II study of S-1 and concurrent radiotherapy with versus without induction chemotherapy of gemcitabine for locally advanced pancreatic cancer (LAPC): Final analysis of JCOG1106

Author

Ioka, T., primary, Fukutomi, A., additional, Mizusawa, J., additional, Katayama, H., additional, Nakamura, S., additional, Ito, Y., additional, Hiraoka, N., additional, Ueno, M., additional, Ikeda, M., additional, Sugimori, K., additional, Shimizu, K., additional, Okusaka, T., additional, Ozaka, M., additional, Yanagimoto, H., additional, Nakamori, S., additional, Azuma, T., additional, Hosokawa, A., additional, Sata, N., additional, Mine, T., additional, and Furuse, J., additional

Published
2016
Full Text
View/download PDF

24. Observational study of FOLFIRINOX (FFX) for unresectable/recurrent pancreatic cancer (PC) in Japanese patients (pts)(JASPAC 06): final results

Author

Mizuno, N., primary, Todaka, A., additional, Mori, K., additional, Boku, N., additional, Ozaka, M., additional, Ueno, H., additional, Kobayashi, S., additional, Uesugi, K., additional, Kobayashi, N., additional, Hayashi, H., additional, Sudo, K., additional, Okano, N., additional, Horita, Y., additional, Kamei, K., additional, Yukisawa, S., additional, Nakamori, S., additional, Yachi, Y., additional, Henmi, T., additional, Kobayashi, M., additional, and Fukutomi, A., additional

Published
2016
Full Text
View/download PDF

25. P-052 Phase II study of biweekly cetuximab and irinotecan as third-line therapy in patients with pre-treated KRAS exon2 wild-type metastatic colorectal cancer

Author

Osumi, H., primary, Shinozaki, E., additional, Suenaga, M., additional, Matsusaka, S., additional, Nakayama, I., additional, Wakatsuki, T., additional, Ogura, M., additional, Ozaka, M., additional, Takashi, I., additional, Takahari, D., additional, Chin, K., additional, Mizunuma, N., additional, and Yamaguchi, K., additional

Published
2016
Full Text
View/download PDF

27. 2313 Multicenter retrospective analysis of pancreatic acinar cell carcinoma: Overall survival and potential benefit of platinum- or irinotecan-containing chemotherapy

Author

Takahashi, H., primary, Ikeda, M., additional, Shiba, S., additional, Imaoka, H., additional, Todaka, A., additional, Shioji, K., additional, Yane, K., additional, Kojima, Y., additional, Kobayashi, S., additional, Asagi, A., additional, Ozaka, M., additional, Takada, R., additional, Suzuki, T., additional, Horiguchi, S., additional, Kasuga, A., additional, Suzuki, E., additional, Terashima, T., additional, Ueno, M., additional, Morizane, C., additional, and Furuse, J., additional

Published
2015
Full Text
View/download PDF

29. P-203 KRAS mutational variations and characteristics in colorectal cancer(CRC): Analysis of over 1600 patients in single institute

Author

Shinozaki, E., primary, Miki, Y., additional, Ueno, M., additional, Igarashi, M., additional, Nakayama, I., additional, Osumi, H., additional, Suenaga, M., additional, Chin, K., additional, Ogura, M., additional, Ozaka, M., additional, Matsusaka, S., additional, Takahari, D., additional, Takashi, I., additional, Wakatsuki, T., additional, Yamaguchi, T., additional, and Mizunuma, N., additional

Published
2015
Full Text
View/download PDF

30. P-231 All RAS mutation predict for poor clinical outcomes after metastasectomy in patients with metastatic colorectal cancer

Author

Osumi, H., primary, Shinozaki, E., additional, Suenaga, M., additional, Kumekawa, Y., additional, Ozaka, M., additional, Ogura, M., additional, Matsusaka, S., additional, Chin, K., additional, Ueno, M., additional, Saiura, A., additional, Okumura, S., additional, Mizunuma, N., additional, Miki, Y., additional, and Yamaguchi, T., additional

Published
2015
Full Text
View/download PDF

40. 621PD - Randomized phase II study of S-1 and concurrent radiotherapy with versus without induction chemotherapy of gemcitabine for locally advanced pancreatic cancer (LAPC): Final analysis of JCOG1106

Author

Ioka, T., Fukutomi, A., Mizusawa, J., Katayama, H., Nakamura, S., Ito, Y., Hiraoka, N., Ueno, M., Ikeda, M., Sugimori, K., Shimizu, K., Okusaka, T., Ozaka, M., Yanagimoto, H., Nakamori, S., Azuma, T., Hosokawa, A., Sata, N., Mine, T., and Furuse, J.

Published
2016
Full Text
View/download PDF

50. Propofol in low doses causes redistribution of body heat in male volunteers.

Author

Noguchi, I., Matsukawa, T., Ozaka, M., and Amemiya, Y.

Subjects
CONSCIOUS sedation, CARDIOVASCULAR diseases, PSYCHOLOGICAL stress
Abstract

Examines the efficacy of propofol sedation in reducing cardiovascular and mental stress in dental patients with phobias about dentistry. Effects of propofol on body temperatures in male volunteers; Redistribution of heat from the core to the periphery; Inhibition of tonic vasoconstriction by the induction of anaesthesia.

Published
2002
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results